Drug – bio-affecting and body treating compositions – Inorganic active ingredient containing – Heavy metal or compound thereof
Reexamination Certificate
1996-08-23
2004-04-13
Pak, John (Department: 1616)
Drug, bio-affecting and body treating compositions
Inorganic active ingredient containing
Heavy metal or compound thereof
C514S908000
Reexamination Certificate
active
06720011
ABSTRACT:
The present invention is directed to an injectable, intravenous pharmaceutical composition for the treatment of cancer.
Leukemia is one form of cancer. It is also known as cancer of the blood. It is a life-threatening malignant neoplasm of the hematopoietic system. The survival period of patients diagnosed with the disease is generally about three to six months with no medical intervention. Acute promyelocytic leukemia (APL) is a subtype of leukemia with a high rate of early mortality and a low long-term survival rate where there is lack of medical treatment. Acute myeloid leukemia (AML) is another subtype of leukemia.
In developed countries, the current principal method of cancer treatment is by chemotherapy. For AML, the complete remission rate when treated with chemotherapy is 75% in children and 78% in adults; with a five year disease-free survival (DFS) rate of 35% to 40%. When chemotherapy is combined with bone marrow transplant, the four year DFS is increased to 59%.
In China, the complete remission rate for AML is from 60% to 70%, and the five year DFS is less than 10%.
For APL, it has been shown that with retinoic acid, a complete remission rate of 85% can be achieved. However, it has been found that the relapse rate is high. Where relapse has occurred, it has been found that in re-treatment with the same or similar chemotherapeutic agents, the efficacy is much reduced while the undesirable side effects are enhanced. Most of the patients cannot endure re-treatment and the treatment fails.
The present invention is directed to an intravenous drip composition for the treatment of cancers. The cancers treatable include leukemia, hepatoma and lymphoma.
The effectiveness of the composition of the present invention is demonstrated by clinical trials with patients suffering from APL. The results show that the composition of the present invention is very effective against the cancer cells and produce limited undesirable side effects.
The intravenous composition of the present invention comprises a mixture of arsenic trioxide, sodium chloride and water. More particularly, the composition of the present invention comprises about 1 g-10 g arsenic trioxide, 8 g of sodium chloride and 1000 mL of sterile water suitable for intravenous injection. The composition is prepared by boiling 1000 mL of water, adding the arsenic trioxide to the boiling water and continuing to boil the mixture for a further period of about 30 minutes. After the arsenic trioxide has completely dissolved, the sodium chloride is added. Sterile water is further added to provide a final volume of 1000 mL. The solution is then sterile filtered to ensure injectability by using a G3 glass filter funnel. The filtered solution is introduced into ampules under sterile conditions.
The Pharmacology of the Composition of the Invention
Experimental results demonstrate that the intravenous composition of the present invention exert a strong abruptive effect on the membranes of cancer cells, such as leukemic cells. It inhibits DNA/RNA synthesis and reduces the proliferation of the leukemic cells. The experiments, both in vivo and in vitro have demonstrated that the intravenous composition of the present invention is effective in destroying leukemic cells while inducing increased cell differentiation to produce normal cells. Additionally, the recovery of hematopoietic function is accelerated. It has also been found that the composition of the present invention can pass through the blood-brain barrier.
The increased cell differentiation and formation of normal cells was observed by electronic microscopic tissue examination after treatment with the composition of the present invention.
Method of Administration
An effective daily dose for an adult has been found to be 10 mL of a composition containing 10 g/L of arsenic trioxide added to 500 mL of a 10% glucose solution. The composition can be administered as an intravenous drip. Each course of treatment takes about four weeks. The amount of the composition used should be adjusted based on the concentration of the arsenic trioxide in the composition. The appropriate dose is decreased accordingly for children.
A comparison of the results with other chemotherapeutic agents currently in use shows that higher remission and long term survival rates are obtained with the composition of the present invention. A remission rate of 84% and a DFS of 21 years have been observed.
Laboratory experiments indicate that the composition shows a strong abruptive effect on the membranes of leukemic cells. It also inhibits DNA/RNA synthesis in such cells, reduces the rate of proliferation of leukemic cells and destroys the leukemic cells. The composition also is observed to induce cell differentiation to produce normal cells and restore hematopoietic function. With the composition of the present invention, the development of leukemia in the central nervous system is seldom observed. This indicates that the composition of the present invention can pass through the blood-brain barrier, an obviously superior characteristic over currently used chemotherapeutic agents. Another advantage of the composition of the present invention is that it promotes the proliferation of megakaryotic cells to quickly restore platelet function. As a result, bleeding from hemostatic dysfunction is rare. At the same time, it promotes the production of normal cells by the bone marrow to restore normal hemopoietic function.
A national award for scientific progress second class award has been received for the intravenous composition of the present invention.
The intravenous composition of the present invention comprise 1 g-10 g of arsenic trioxide, 8 g of sodium chloride and sterile water. The composition may be prepared by boiling the ingredients until a clear solution is obtained. The solution is then filtered and sterilized. The detailed procedure for the preparation of the composition comprises boiling 1000 mL of sterile water for injection, adding arsenic trioxide, boiling for a further 30 minutes until the arsenic trioxide is completely dissolved, adding sodium chloride and q.s. with water to 1000 mL. The solution is then sterile filtered through a G3 glass filter funnel and infused into ampules under sterile conditions.
REFERENCES:
patent: 95/01789 (1995-01-01), None
Huang, S. L. et al., Chinese J: Hematol., vol. 16, 1995, pp. 26-28.*
Kwong, Y. L. et al., “Delicious Poison: Arsenic Trioxide for the Treatment of Leukemia,” Blood, vol. 89(9), 1997, pp. 3487-3488.*
Shen, Zhi-Xiang et al., “Use of Arsenic Trioxide (As2O3) in the Treatment of Acute Promyelocytic Leukemia (Apl) . . . ” Blood, vol. 89(9), 1997, p. 3354.*
The Merck Index, 10th ed., Rahway (NJ), Merck & Co., Inc., 1983, p. 117, entry 824.*
Chemical Abstracts 130:115060, 1999.*
Shimotsuura, S. et al., “Studies on the antineoplasmic actions of As203,” Shikwa Gakuho, vol. 86, pp. 1237-1253, 1986.
Fluka 1995/96 Catalog, p. 152-153, Jul. 1995.*
USP Dictionary of USAN and International Drug Names, United States Pharmacopeial Conventions, Inc., Rockville, MD, p. 59, Nov. 1994.*
Zhang Peng et al., “Treatment of acute promyelocytic Leukemia with intravenous arsenic trioxide,” Chinese Journal of Hematology, vol. 17, No. 2, pp. 58-60, Feb. 1996.*
Guo-Qiang Chen et al., “In vitro studies on cellular and molecular mechanisms of arsenic trioxide . . . ” Blood, vol. 88, No. 3, pp. 1052-1061, Aug. 1, 1996.*
Shibuya, “Experimental arsenous oxide poisoning,” Tokyo Jikeikai Ika Daigaku Zasshi, vol. 86, No. 4, pp. 563-575, 1971.*
Reichl et al., “Effect of arsenic on cellular metabolism after single or repeated injection in guinea pigs,” Arch. Toxicol., Suppl. 13, pp. 363-365, 1989.*
Remington's Pharmaceutical Sciences, Mark Publishing Co., Easton, PA, pp. 1570-1580, 1990.*
Zhang Peng et al., “APL Treatment with “713”—Clinical observation on 117 cases and mechanism study,” The Academic Journal of Harbin Medical University, Issue 3, p. 243, Jun. 1995.*
Chinese Medical Association, Heilongjiang Branch, “Letter on Historical Facts Regarding the Development of “Ai Ling No. 1” and t
Dichter Eric A.
Pak John
Zielinski Robert F.
LandOfFree
Injectable composition for cancer treatment does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Injectable composition for cancer treatment, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Injectable composition for cancer treatment will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3248418